A Randomized, Open-Label, Parallel Group Study of Alpha-1 Antitrypsin Therapy in Hospitalized Patients With COVID-19.
BACKGROUND Alpha-1 antitrypsin (AAT) reduces production of several pro-inflammatory cytokines. Increased inflammatory cytokines are prominent in the hyperinflammatory state associated with severe COVID-19 infection. The study objective was to determine if administration of AAT reduced the severity of COVID-19 pneumonia...